Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma plans to use its presence at the LSX Nordic Congress in Copenhagen on May 19-20, 2026 to engage with investors and potential pharmaceutical partners as it advances its inflammation-focused pipeline. Senior executives, including the CEO, CBO, and CFO, will hold meetings, deliver a company presentation, and join a panel on Nordic deal-making, underscoring the firm’s push to secure strategic collaborations and funding.
The timing of the congress is pivotal for SynAct, with topline Phase 2b ADVANCE data for its lead drug resomelagon in newly diagnosed rheumatoid arthritis patients approaching. By showcasing its pro-resolution therapy strategy at a leading Nordic life sciences partnering and investment forum, the company aims to strengthen its industry positioning and support the next phase of development for treatments targeting millions of patients with autoimmune and acute inflammatory conditions.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on developing pro-resolution therapies to treat inflammation-driven autoimmune and acute inflammatory diseases, including rheumatoid arthritis. Its lead candidate, resomelagon, targets unmet medical needs in newly diagnosed patients and aims to modulate inflammatory processes through resolution rather than broad immunosuppression.
Average Trading Volume: 195,935
Technical Sentiment Signal: Sell
Current Market Cap: SEK906.6M
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.